{
    "nct_id": "NCT04296305",
    "official_title": "Effect of Opioid Infusion Rate on Abuse Liability Potential and Analgesic Efficacy of Intravenous Hydromorphone Among Inpatients With Cancer Pain: A Randomized Crossover Trial",
    "inclusion_criteria": "* Hospitalized patients with diagnosis of cancer\n* History of moderate to severe cancer related pain, defined as Numerical Rating Scale (NRS) pain score >= 4/10\n* Receiving no or only on as needed doses of opioids\n* Normal cognitive status, defined as a normal state of arousal and an absence of obvious clinical findings of confusion, memory deficits or concentration deficits or a Memorial Delirium Assessment Scale (MDAS) score of < 13\n* Ability to read and communicate in the English language\n* Written informed consent from patient\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindications to opioids, or history of opioid allergy\n* Inability to secure IV access\n* Known history or evidence of nonmedical opioid use (e.g. abuse, misuse, addiction)\n* Oxygen saturations < 92% or respiratory rate < 12 breaths/minute on initial assessment\n* Resting heart rate > 120 on initial assessment\n* Systolic blood pressure > 180 < 90 mmHg or diastolic pressure > 100 < 60 mmHg on initial assessment\n* Patients receiving scheduled chronic opioid therapy (defined as the treatment of pain with opioids for >= 7 days)\n* Moderate to severe renal insufficiency (defined as glomerular filtration rate [GFR] < 60 ml/min/1.73 m^2)\n* Hepatic insufficiency (defined as alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times the highest normal value, or total bilirubin > 1.5 times the highest normal value)",
    "miscellaneous_criteria": ""
}